BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther 2014;22:102-11. [PMID: 24135899 DOI: 10.1038/mt.2013.240] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 9.9] [Reference Citation Analysis]
Number Citing Articles
1 Feola S, Russo S, Ylösmäki E, Cerullo V. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. Pharmacol Ther 2021;236:108103. [PMID: 34954301 DOI: 10.1016/j.pharmthera.2021.108103] [Reference Citation Analysis]
2 Chaurasiya S, Fong Y, Warner SG. Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges. Cancers (Basel) 2020;12:E1699. [PMID: 32604787 DOI: 10.3390/cancers12061699] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
3 Santiago DN, Heidbuechel JPW, Kandell WM, Walker R, Djeu J, Engeland CE, Abate-Daga D, Enderling H. Fighting Cancer with Mathematics and Viruses. Viruses 2017;9:E239. [PMID: 28832539 DOI: 10.3390/v9090239] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
4 Jin J, Wang R, Yang J, Hu H, Wang D, Cai L, Fang Z, Dong S, Hu S, Wang Y, Liu B. BiTEs expressed by an oncolytic herpes simplex virus type 2 can transform heterologous T cells into uniform tumor killer cells. Hum Gene Ther 2022. [PMID: 35272497 DOI: 10.1089/hum.2021.277] [Reference Citation Analysis]
5 Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019;7:6. [PMID: 30626434 DOI: 10.1186/s40425-018-0495-7] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 23.3] [Reference Citation Analysis]
6 Jebar AH, Vile RG, Melcher AA, Griffin S, Selby PJ, Errington-mais F. Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. Journal of General Virology 2015;96:1533-50. [DOI: 10.1099/vir.0.000098] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
7 Guo ZS, Liu Z, Kowalsky S, Feist M, Kalinski P, Lu B, Storkus WJ, Bartlett DL. Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Front Immunol 2017;8:555. [PMID: 28555136 DOI: 10.3389/fimmu.2017.00555] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 8.6] [Reference Citation Analysis]
8 Heidbuechel JPW, Abate-Daga D, Engeland CE, Enderling H. Mathematical Modeling of Oncolytic Virotherapy. Methods Mol Biol 2020;2058:307-20. [PMID: 31486048 DOI: 10.1007/978-1-4939-9794-7_21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kochneva GV, Sivolobova GF, Tkacheva AV, Gorchakov AA, Kulemzin SV. Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer. Mol Biol 2020;54:1-12. [DOI: 10.1134/s0026893320010100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Jefferson A, Cadet VE, Hielscher A. The mechanisms of genetically modified vaccinia viruses for the treatment of cancer. Crit Rev Oncol Hematol. 2015;95:407-416. [PMID: 25900073 DOI: 10.1016/j.critrevonc.2015.04.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
11 Samaha H, El Naggar S, Ahmed N. Armed hunter killers: discerning the role of adoptive T-cell transfer for glioblastoma. Immunotherapy 2015;7:481-5. [DOI: 10.2217/imt.15.22] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
12 Cuddington BP, Verschoor M, Ashkar A, Mossman KL. Enhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma. Mol Ther Oncolytics 2015;2:15004. [PMID: 27119103 DOI: 10.1038/mto.2015.4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
13 Russell L, Peng KW, Russell SJ, Diaz RM. Oncolytic Viruses: Priming Time for Cancer Immunotherapy. BioDrugs 2019;33:485-501. [PMID: 31321623 DOI: 10.1007/s40259-019-00367-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 21.5] [Reference Citation Analysis]
14 Guedan S, Alemany R. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.Front Immunol. 2018;9:2460. [PMID: 30405639 DOI: 10.3389/fimmu.2018.02460] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
15 Hu PY, Fan XM, Zhang YN, Wang SB, Wan WJ, Pan HY, Mou XZ. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them. Appl Microbiol Biotechnol 2020;104:8231-42. [PMID: 32816087 DOI: 10.1007/s00253-020-10802-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Ylösmäki E, Cerullo V. Design and application of oncolytic viruses for cancer immunotherapy. Curr Opin Biotechnol 2020;65:25-36. [PMID: 31874424 DOI: 10.1016/j.copbio.2019.11.016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
17 Ravirala D, Mistretta B, Gunaratne PH, Pei G, Zhao Z, Zhang X. Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy. J Immunother Cancer 2021;9:e002454. [PMID: 34230110 DOI: 10.1136/jitc-2021-002454] [Reference Citation Analysis]
18 Cuddington BP, Mossman KL. Oncolytic bovine herpesvirus type 1 as a broad spectrum cancer therapeutic. Curr Opin Virol 2015;13:11-6. [PMID: 25846987 DOI: 10.1016/j.coviro.2015.03.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
19 Sato-Dahlman M, LaRocca CJ, Yanagiba C, Yamamoto M. Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination. Cancers (Basel) 2020;12:E1295. [PMID: 32455560 DOI: 10.3390/cancers12051295] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
20 Tsun A, Miao XN, Wang CM, Yu DC. Oncolytic Immunotherapy for Treatment of Cancer.Adv Exp Med Biol. 2016;909:241-283. [PMID: 27240460 DOI: 10.1007/978-94-017-7555-7_5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
21 Wei PS, Chen YJ, Lin SY, Chuang KH, Sheu MT, Ho HO. In situ subcutaneously injectable thermosensitive PEG-PLGA diblock and PLGA-PEG-PLGA triblock copolymer composite as sustained delivery of bispecific anti-CD3 scFv T-cell/anti-EGFR Fab Engager (BiTEE). Biomaterials 2021;278:121166. [PMID: 34634663 DOI: 10.1016/j.biomaterials.2021.121166] [Reference Citation Analysis]
22 Zhang B, Cheng P. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy. Mol Cancer 2020;19:158. [PMID: 33172438 DOI: 10.1186/s12943-020-01275-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
23 Torres-Domínguez LE, McFadden G. Poxvirus oncolytic virotherapy. Expert Opin Biol Ther 2019;19:561-73. [PMID: 30919708 DOI: 10.1080/14712598.2019.1600669] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
24 Wang L, Chard Dunmall LS, Cheng Z, Wang Y. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment. J Immunother Cancer 2022;10:e004167. [PMID: 35640930 DOI: 10.1136/jitc-2021-004167] [Reference Citation Analysis]
25 Rosewell Shaw A, Suzuki M. Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment.Front Immunol. 2018;9:2103. [PMID: 30298067 DOI: 10.3389/fimmu.2018.02103] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
26 Yu J, Li Y, Zhong M, Yang J, Zhou D, Zhao B, Cao Y, Yan H, Zhang E, Yang Y, Feng Z, Qi X, Yan H. Improved immune response against HIV-1 Env antigen by enhancing EEV production via a K151E mutation in the A34R gene of replication-competent vaccinia virus Tiantan. Antiviral Research 2018;153:49-59. [DOI: 10.1016/j.antiviral.2018.03.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Suryadevara CM, Gedeon PC, Sanchez-Perez L, Verla T, Alvarez-Breckenridge C, Choi BD, Fecci PE, Sampson JH. Are BiTEs the "missing link" in cancer therapy? Oncoimmunology 2015;4:e1008339. [PMID: 26155413 DOI: 10.1080/2162402X.2015.1008339] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 5.9] [Reference Citation Analysis]
28 Cao F, Nguyen P, Hong B, DeRenzo C, Rainusso NC, Rodriguez Cruz T, Wu MF, Liu H, Song XT, Suzuki M, Wang LL, Yustein JT, Gottschalk S. Engineering Oncolytic Vaccinia Virus to redirect Macrophages to Tumor Cells. Adv Cell Gene Ther 2021;4:e99. [PMID: 33829146 DOI: 10.1002/acg2.99] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 de Sostoa J, Fajardo CA, Moreno R, Ramos MD, Farrera-Sal M, Alemany R. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. J Immunother Cancer 2019;7:19. [PMID: 30683154 DOI: 10.1186/s40425-019-0505-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 16.3] [Reference Citation Analysis]
30 Davola ME, Vito A, Wei J, El-Sayes N, Workenhe S, Mossman KL. Genetic modification of oncolytic viruses to enhance antitumor immunity. Methods Enzymol 2020;635:231-50. [PMID: 32122548 DOI: 10.1016/bs.mie.2019.05.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Gorbet MJ, Ranjan A. Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy. Pharmacol Ther 2020;207:107456. [PMID: 31863820 DOI: 10.1016/j.pharmthera.2019.107456] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
32 Wang G, Kang X, Chen KS, Jehng T, Jones L, Chen J, Huang XF, Chen SY. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat Commun 2020;11:1395. [PMID: 32170083 DOI: 10.1038/s41467-020-15229-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 9.5] [Reference Citation Analysis]
33 Crupi MJF, Bell JC, Singaravelu R. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses. Stem Cells 2019;37:716-23. [PMID: 30875126 DOI: 10.1002/stem.3004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
34 Kontermann RE, Ungerechts G, Nettelbeck DM. Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics. MAbs 2021;13:1982447. [PMID: 34747345 DOI: 10.1080/19420862.2021.1982447] [Reference Citation Analysis]
35 Groeneveldt C, Kinderman P, van den Wollenberg DJM, van den Oever RL, Middelburg J, Mustafa DAM, Hoeben RC, van der Burg SH, van Hall T, van Montfoort N. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy. J Immunother Cancer 2020;8:e001191. [PMID: 33082167 DOI: 10.1136/jitc-2020-001191] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
36 Fisher K, Hazini A, Seymour LW. Tackling HLA Deficiencies Head on with Oncolytic Viruses. Cancers (Basel) 2021;13:719. [PMID: 33578735 DOI: 10.3390/cancers13040719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
37 Ajina A, Maher J. Prospects for combined use of oncolytic viruses and CAR T-cells.J Immunother Cancer. 2017;5:90. [PMID: 29157300 DOI: 10.1186/s40425-017-0294-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 8.6] [Reference Citation Analysis]
38 Lan Q, Xia S, Wang Q, Xu W, Huang H, Jiang S, Lu L. Development of oncolytic virotherapy: from genetic modification to combination therapy. Front Med 2020;14:160-84. [PMID: 32146606 DOI: 10.1007/s11684-020-0750-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
39 Mardi A, Shirokova AV, Mohammed RN, Keshavarz A, Zekiy AO, Thangavelu L, Mohamad TAM, Marofi F, Shomali N, Zamani A, Akbari M. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction. Cancer Cell Int 2022;22:168. [PMID: 35488303 DOI: 10.1186/s12935-022-02585-z] [Reference Citation Analysis]
40 Gottschalk S, Rooney CM. Harnessing the immune system to potentiate oncolytics. Mol Ther 2014;22:239-40. [PMID: 24487560 DOI: 10.1038/mt.2013.295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Shi T, Song X, Wang Y, Liu F, Wei J. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.Front Immunol. 2020;11:683. [PMID: 32411132 DOI: 10.3389/fimmu.2020.00683] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 11.5] [Reference Citation Analysis]
42 Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14:559-567. [PMID: 24990523 DOI: 10.1038/nrc3770] [Cited by in Crossref: 358] [Cited by in F6Publishing: 350] [Article Influence: 44.8] [Reference Citation Analysis]
43 Sánchez-Sampedro L, Perdiguero B, Mejías-Pérez E, García-Arriaza J, Di Pilato M, Esteban M. The evolution of poxvirus vaccines. Viruses 2015;7:1726-803. [PMID: 25853483 DOI: 10.3390/v7041726] [Cited by in Crossref: 101] [Cited by in F6Publishing: 87] [Article Influence: 14.4] [Reference Citation Analysis]
44 Guo ZS, Lotze MT, Zhu Z, Storkus WJ, Song XT. Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy. Biomedicines 2020;8:E204. [PMID: 32664210 DOI: 10.3390/biomedicines8070204] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
45 Song K, Viskovska M. Design and Engineering of Deimmunized Vaccinia Viral Vectors. Biomedicines 2020;8:E491. [PMID: 33187060 DOI: 10.3390/biomedicines8110491] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Pelin A, Boulton S, Tamming LA, Bell JC, Singaravelu R. Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity. Expert Opin Biol Ther 2020;20:1083-97. [PMID: 32297534 DOI: 10.1080/14712598.2020.1757066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
47 Li H, Er Saw P, Song E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol 2020;17:451-61. [PMID: 32313210 DOI: 10.1038/s41423-020-0417-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
48 Oelkrug C, Ramage JM. Enhancement of T cell recruitment and infiltration into tumours. Clin Exp Immunol 2014;178:1-8. [PMID: 24828133 DOI: 10.1111/cei.12382] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 9.9] [Reference Citation Analysis]
49 Wang Z, Guo K, Liu Y, Huang C, Wu M. Dynamic impact of virome on colitis and colorectal cancer: Immunity, inflammation, prevention and treatment. Semin Cancer Biol 2021:S1044-579X(21)00254-6. [PMID: 34656791 DOI: 10.1016/j.semcancer.2021.10.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Martin NT, Bell JC. Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones. Mol Ther 2018;26:1414-22. [PMID: 29703699 DOI: 10.1016/j.ymthe.2018.04.001] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 14.0] [Reference Citation Analysis]
51 Scott EM, Jacobus EJ, Lyons B, Frost S, Freedman JD, Dyer A, Khalique H, Taverner WK, Carr A, Champion BR, Fisher KD, Seymour LW, Duffy MR. Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples. J Immunother Cancer 2019;7:320. [PMID: 31753017 DOI: 10.1186/s40425-019-0807-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 7.7] [Reference Citation Analysis]
52 Zhang H, Zhang Y, Dong J, Zuo S, Meng G, Wu J, Wei J. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8+ T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma. Cell Oncol (Dordr) 2021. [PMID: 34491549 DOI: 10.1007/s13402-021-00633-w] [Reference Citation Analysis]
53 Twumasi-boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer 2018;18:419-32. [DOI: 10.1038/s41568-018-0009-4] [Cited by in Crossref: 143] [Cited by in F6Publishing: 139] [Article Influence: 35.8] [Reference Citation Analysis]
54 Arnone CM, Polito VA, Mastronuzzi A, Carai A, Diomedi FC, Antonucci L, Petrilli LL, Vinci M, Ferrari F, Salviato E, Scarsella M, De Stefanis C, Weber G, Quintarelli C, De Angelis B, Brenner MK, Gottschalk S, Hoyos V, Locatelli F, Caruana I, Del Bufalo F. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer 2021;9:e001930. [PMID: 33963009 DOI: 10.1136/jitc-2020-001930] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Iwahori K, Kakarla S, Velasquez MP, Yu F, Yi Z, Gerken C, Song XT, Gottschalk S. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther 2015;23:171-8. [PMID: 25142939 DOI: 10.1038/mt.2014.156] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
56 Guo ZS, Liu Z, Bartlett DL. Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Front Oncol 2014;4:74. [PMID: 24782985 DOI: 10.3389/fonc.2014.00074] [Cited by in Crossref: 114] [Cited by in F6Publishing: 142] [Article Influence: 14.3] [Reference Citation Analysis]
57 de Gruijl TD, Janssen AB, van Beusechem VW. Arming oncolytic viruses to leverage antitumor immunity.Expert Opin Biol Ther. 2015;15:959-971. [PMID: 25959450 DOI: 10.1517/14712598.2015.1044433] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
58 Russell L, Peng KW. The emerging role of oncolytic virus therapy against cancer. Chin Clin Oncol 2018;7:16. [PMID: 29764161 DOI: 10.21037/cco.2018.04.04] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 12.3] [Reference Citation Analysis]
59 Guo ZS, Bartlett DL. Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land. Cancer Gene Ther 2014;21:261-3. [PMID: 25034971 DOI: 10.1038/cgt.2014.31] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
60 Jin KT, Du WL, Liu YY, Lan HR, Si JX, Mou XZ. Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements. Cancers (Basel) 2021;13:588. [PMID: 33546172 DOI: 10.3390/cancers13040588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Khalique H, Baugh R, Dyer A, Scott EM, Frost S, Larkin S, Lei-Rossmann J, Seymour LW. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy. J Immunother Cancer 2021;9:e001292. [PMID: 33820820 DOI: 10.1136/jitc-2020-001292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
62 Altomonte J, Ebert O. Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma. Front Oncol 2014;4:85. [PMID: 24795862 DOI: 10.3389/fonc.2014.00085] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
63 Conrad SJ, Liu J. Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes. Methods Mol Biol 2019;1937:189-209. [PMID: 30706397 DOI: 10.1007/978-1-4939-9065-8_11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
64 Yang X, Huang B, Deng L, Hu Z. Progress in gene therapy using oncolytic vaccinia virus as vectors. J Cancer Res Clin Oncol 2018;144:2433-40. [DOI: 10.1007/s00432-018-2762-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
65 Holay N, Kim Y, Lee P, Gujar S. Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines. Front Immunol 2017;8:800. [PMID: 28751892 DOI: 10.3389/fimmu.2017.00800] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
66 Santos Apolonio J, Lima de Souza Gonçalves V, Cordeiro Santos ML, Silva Luz M, Silva Souza JV, Rocha Pinheiro SL, de Souza WR, Sande Loureiro M, de Melo FF. Oncolytic virus therapy in cancer: A current review. World J Virol 2021; 10(5): 229-255 [PMID: 34631474 DOI: 10.5501/wjv.v10.i5.229] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Alemany R. Oncolytic Adenoviruses in Cancer Treatment. Biomedicines 2014;2:36-49. [PMID: 28548059 DOI: 10.3390/biomedicines2010036] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
68 Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 2018;131:30-8. [PMID: 29118005 DOI: 10.1182/blood-2017-06-741058] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 15.0] [Reference Citation Analysis]
69 Cuddington BP, Mossman KL. Identifying roadblocks to successful oncolytic virotherapy: what are they and how do we approach them? Future Virology 2014;9:695-7. [DOI: 10.2217/fvl.14.48] [Reference Citation Analysis]
70 Chiu M, Armstrong EJL, Jennings V, Foo S, Crespo-Rodriguez E, Bozhanova G, Patin EC, McLaughlin M, Mansfield D, Baker G, Grove L, Pedersen M, Kyula J, Roulstone V, Wilkins A, McDonald F, Harrington K, Melcher A. Combination therapy with oncolytic viruses and immune checkpoint inhibitors. Expert Opin Biol Ther 2020;20:635-52. [PMID: 32067509 DOI: 10.1080/14712598.2020.1729351] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
71 Boagni DA, Ravirala D, Zhang SX. Current strategies in engaging oncolytic viruses with antitumor immunity. Mol Ther Oncolytics 2021;22:98-113. [PMID: 34514092 DOI: 10.1016/j.omto.2021.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Barrow P, Dujardin JC, Fasel N, Greenwood AD, Osterrieder K, Lomonossoff G, Fiori PL, Atterbury R, Rossi M, Lalle M. Viruses of protozoan parasites and viral therapy: Is the time now right? Virol J 2020;17:142. [PMID: 32993724 DOI: 10.1186/s12985-020-01410-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Lei W, Ye Q, Hao Y, Chen J, Huang Y, Yang L, Wang S, Qian W. CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma. Blood Cancer J 2022;12:35. [PMID: 35228544 DOI: 10.1038/s41408-022-00634-4] [Reference Citation Analysis]
74 Aitken AS, Roy DG, Bourgeois-Daigneault MC. Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines 2017;5:E3. [PMID: 28536346 DOI: 10.3390/biomedicines5010003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
75 Li F, Sheng Y, Hou W, Sampath P, Byrd D, Thorne S, Zhang Y. CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency. J Immunother Cancer 2020;8:e000131. [PMID: 32098828 DOI: 10.1136/jitc-2019-000131] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
76 Jamieson TR, Poutou J, Ilkow CS. Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment. Cytokine & Growth Factor Reviews 2020;56:102-14. [DOI: 10.1016/j.cytogfr.2020.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Iwahori K, Shintani Y, Funaki S, Yamamoto Y, Matsumoto M, Yoshida T, Morimoto-Okazawa A, Kawashima A, Sato E, Gottschalk S, Okumura M, Kumanogoh A, Wada H. Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment. Sci Rep 2019;9:2636. [PMID: 30796310 DOI: 10.1038/s41598-019-39345-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
78 Heidbuechel JPW, Engeland CE. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J Hematol Oncol 2021;14:63. [PMID: 33863363 DOI: 10.1186/s13045-021-01075-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
79 Guo H, Zhao L, Zhu J, Chen P, Wang H, Jiang M, Liu X, Sun H, Zhao W, Zheng Z, Li W, Chen B, Fang Q, Yang M, He Y, Yang Y. Microbes in lung cancer initiation, treatment, and outcome: Boon or bane? Semin Cancer Biol 2021:S1044-579X(21)00154-1. [PMID: 34029741 DOI: 10.1016/j.semcancer.2021.05.025] [Reference Citation Analysis]
80 Badrinath N, Heo J, Yoo SY. Viruses as nanomedicine for cancer. Int J Nanomedicine 2016;11:4835-47. [PMID: 27703350 DOI: 10.2147/IJN.S116447] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
81 Bastin D, Walsh SR, Al Saigh M, Wan Y. Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies. Biomedicines 2016;4:E21. [PMID: 28536388 DOI: 10.3390/biomedicines4030021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
82 Chira S, Jackson CS, Oprea I, Ozturk F, Pepper MS, Diaconu I, Braicu C, Raduly LZ, Calin GA, Berindan-Neagoe I. Progresses towards safe and efficient gene therapy vectors. Oncotarget 2015;6:30675-703. [PMID: 26362400 DOI: 10.18632/oncotarget.5169] [Cited by in Crossref: 116] [Cited by in F6Publishing: 106] [Article Influence: 19.3] [Reference Citation Analysis]
83 Evgin L, Vile RG. Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals? Cancers (Basel) 2021;13:1106. [PMID: 33807553 DOI: 10.3390/cancers13051106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T. Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Cancers (Basel) 2021;13:287. [PMID: 33466732 DOI: 10.3390/cancers13020287] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
85 Moaven O, Mangieri CW, Stauffer JA, Anastasiadis PZ, Borad MJ. Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy. JCO Precis Oncol 2021;5:PO. [PMID: 34250395 DOI: 10.1200/PO.21.00003] [Reference Citation Analysis]
86 Scott EM, Duffy MR, Freedman JD, Fisher KD, Seymour LW. Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses. Macromol Biosci 2018;18. [PMID: 28902983 DOI: 10.1002/mabi.201700187] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
87 Zhang S, Rabkin SD. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy? Expert Opin Drug Discov 2021;16:391-410. [PMID: 33232188 DOI: 10.1080/17460441.2021.1850689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
88 Park R, Eshrat F, Al-Jumayli M, Saeed A, Saeed A. Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma. Vaccines (Basel) 2020;8:E447. [PMID: 32784389 DOI: 10.3390/vaccines8030447] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
89 Albelda SM, Thorne SH. Giving oncolytic vaccinia virus more BiTE. Mol Ther 2014;22:6-8. [PMID: 24384909 DOI: 10.1038/mt.2013.271] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
90 Thorne SH. Immunotherapeutic potential of oncolytic vaccinia virus. Front Oncol 2014;4:155. [PMID: 24987615 DOI: 10.3389/fonc.2014.00155] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
91 Goncharova EP, Ruzhenkova JS, Petrov IS, Shchelkunov SN, Zenkova MA. Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro. J Transl Med 2016;14:241. [PMID: 27538520 DOI: 10.1186/s12967-016-1002-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
92 Abd-Aziz N, Poh CL. Development of oncolytic viruses for cancer therapy. Transl Res 2021:S1931-5244(21)00104-3. [PMID: 33905949 DOI: 10.1016/j.trsl.2021.04.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]